The germline genetic variability of the FNTB locus and its clinical relevance for breast cancer is still an open question, particularly since promising preclinical data on FTIs are in contrast to the mostly unsuccessful clinical trials [11,12,13,14,15,16,17]. The gene discussed is FNTB; the disease is breast cancer.